OncoRespon
Homepage - OncoResponse
Seattle, United States · $103.1M raised
- Headquarters
- Seattle, Washington
- Employees
- 11–50
- Business Model
- B2B
- Website
- oncoresponse.com
- Total Funding
- $103.1M
- Last Round
- $13.0M GrantMay 2023
- Rounds
- 4
About
OncoResponse is a clinical-stage immuno-oncology biotech developing cancer immunotherapies using clues from the immune systems of elite responders.
Summary
OncoRespon is a Biotech company based in Seattle, United States. It has raised $103.1M in total across 4 rounds, most recently a $13.0M Grant round in May 2023. Investors include Cancer Prevention and Research Institute of Texas, Oxford Finance and Magnetar Capital.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
May 2023
Sign up to see all 7 rounds
Series A through Grant — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/oncorespon"><img src="https://indexed.vc/api/badge/company/oncorespon" alt="OncoRespon on Indexed.vc" width="260" height="76" /></a>